Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.49 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.46 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | ROS1 | P08922 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1707148 | 0.91 | EGFR (0.54) | LRRK2EGFRALKROS1 | |
| SCHEMBL1707467 | 0.89 | GLO1 (0.58) | SYKGLO1GSK3ALRRK2MAPK15 | |
| SCHEMBL1707873 | 0.87 | EGFR (0.54) | EGFRALKROS1 | |
| SCHEMBL1707581 | 0.86 | GSK3A (0.51) | SYKGLO1GSK3ALRRK2MAPK15 | |
| SCHEMBL1706923 | 0.84 | EGFR (0.55) | EGFRALKROS1 | |
| SCHEMBL1038935 | 0.80 | SYK (0.68) | SYKGLO1EGFRITK | |
| SCHEMBL1039621 | 0.80 | SYK (0.56) | SYKGLO1GSK3ALRRK2MAPK15 | |
| SCHEMBL1037179 | 0.79 | SYK (0.56) | SYKGLO1EGFRAURKAITK | |
| SCHEMBL1707766 | 0.79 | EGFR (0.61) | LRRK2EGFRALKROS1 | |
| SCHEMBL1708502 | 0.79 | GLO1 (0.65) | GLO1GSK3ALRRK2MAPK15CAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | claimed |
| EP-2440534-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2012-04-18 | — | — | EP | claimed |
| WO-2010142766-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-16 | — | — | WO | claimed |
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| EP-2440534-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010142766-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010142766-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | ZAP70, LCK, DPY30 | SYK 11/4885GLO1 4299/4885GSK3A 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.